-
EIF4A3–circEIF2S2 Axis in Colorectal Cancer
2026-08-23
The reference study identifies an EIF4A3–circEIF2S2–miR-646–UHMK1 regulatory axis that links circular RNA biogenesis to colorectal cancer growth, metastasis, and immune suppression. Its combination of expression profiling, loss-of-function studies, rescue experiments, immune co-culture, and xenograft models provides a mechanistic framework for evaluating circEIF2S2 as a disease-relevant biomarker and therapeutic target.
-
DIDS Workflows for Chloride and Tumor Assays
2026-08-22
DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) connects chloride-transport pharmacology with experimentally useful models of cell stress, vascular signaling, and tumor response. This guide emphasizes controlled workflows, vehicle and solubility checks, and assay designs that separate channel effects from the broader consequences of impending cell death.
-
IGF2BP1–THBS1–TLR4 Axis in Pulmonary Fibrosis
2026-08-21
This 2025 study identifies an m6A-dependent IGF2BP1–THBS1–TLR4 pathway that links macrophage glycolytic reprogramming with fibrotic polarization in pulmonary fibrosis. Its knockdown, rescue, and metabolic experiments provide a mechanistic framework for studying how macrophage state influences lung injury and extracellular-matrix remodeling.
-
EGCG Nanoparticles Enhance FLASH Radiotherapy
2026-08-20
A 2026 study reports that functionalized, self-assembled EGCG nanoparticles (BENPs) can increase the oxidative and DNA-damaging effects of FLASH radiotherapy while promoting antitumor immune responses. The work combines cell viability, DNA damage, immunofluorescence, animal efficacy, immune profiling, RNA sequencing, and biosafety analyses to evaluate a radiosensitization strategy.
-
Substance P: From Mechanism to Translational Strategy
2026-08-20
Substance P is a tachykinin neuropeptide that connects CNS signaling with pain transmission, inflammation, and immune response modulation. This thought-leadership article outlines how translational teams can turn its NK-1 receptor biology into more reproducible assays while applying lessons from spectral-interference research without overstating cross-domain evidence.
-
Sisomicin Activity Against Clinical Isolates
2026-08-19
Stewart and Bodey evaluated sisomicin against 565 clinical isolates and found strong in vitro activity against most Gram-negative bacilli, with modest advantages over gentamicin and tobramycin for selected species. The study also exposed cross-resistance among related aminoglycosides, while identifying amikacin as a potentially useful option for many resistant isolates.
-
GPNMB Model Predicts ESCC Immunotherapy Response
2026-08-19
This study identifies circulating soluble GPNMB as a mechanistic and clinically useful marker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By combining plasma GPNMB, CAF-epithelial niche features, and clinicopathological variables, the authors developed a multimodal model with potential value for precision immunotherapy selection.
-
Ponicidin Targets Lin28B/Let-7/PBK in TNBC
2026-08-18
A 2026 European Journal of Medicinal Chemistry study identifies ponicidin as a candidate inhibitor of the Lin28B/Let-7 axis in triple-negative breast cancer. Its integrated computational, biochemical, cellular, and animal-model evidence connects Lin28B binding with Let-7 restoration, PBK suppression, apoptosis, and reduced tumor growth, while also defining important limitations for translation.
-
Pepstatin A for Reliable Cell Assays
2026-08-18
Learn how Pepstatin A (SKU A2571) can help researchers separate aspartic-protease biology from confounding changes in cell viability, proliferation, and cytotoxicity readouts. This scenario-based guide covers mechanism, formulation, dosing, orthogonal validation, and practical supplier selection.
-
Macrophage EP4 Loss Accelerates Atherosclerosis
2026-08-17
The reference study identifies macrophage EP4 deficiency as a driver of atherosclerosis progression, linking receptor loss to CD36-dependent lipid uptake, foam-cell formation, and M1 polarization. Its combination of genetically defined mice, oxLDL-stimulated macrophages, transcriptomics, proteomics, Western blotting, and qPCR provides a mechanistic framework for interpreting how inflammatory and lipid-handling programs converge in plaque disease.
-
Protease Inhibitor Cocktail for Metabolic Assays
2026-08-17
Learn how a Protease Inhibitor Cocktail can protect metabolic assay readouts from degradation without chelating divalent cations. This guide uses ANGPTL4–LPL research to connect sample preservation with stronger decisions in Western blotting, activity assays, and protein extraction.
-
T7 RNA Polymerase for gRNA and mRNA Workflows
2026-08-16
T7 RNA Polymerase converts promoter-bearing DNA into research-grade RNA for gRNA, Cas9 mRNA, antisense, RNAi, and other in vitro workflows. This guide connects template design, reaction setup, quality control, and troubleshooting to the co-delivery strategy reported in a recent LGMN gene-editing study.
-
Ertapenem Sodium Salt in Resistance Research
2026-08-15
Ertapenem sodium salt is more than a broad-spectrum antibacterial reagent: it is a mechanistically informative perturbation for studying penicillin-binding proteins, carbapenemase-mediated resistance, plasmid mobility, and translational exposure. This article connects Ertapenem biology with recent CREC transmission data and provides a practical framework for resistance-focused assay design.
-
T7 RNA Polymerase for In Vitro RNA Synthesis
2026-08-14
T7 RNA Polymerase is a recombinant enzyme expressed in E. coli for promoter-specific RNA synthesis from DNA templates. Product specifications support research workflows using linearized plasmids or suitable PCR products, while recent vaccine evidence shows that RNA platform performance depends on the RNA modality and biological context.
-
How HBsAg Rewires TBK1 Signaling and Autophagy
2026-08-14
The 2025 Cell Death and Disease study identifies a mechanism by which hepatitis B surface antigen redirects TBK1 activity away from IRF3-dependent interferon production and toward early autophagy. Its combination of molecular interaction studies, pharmacological perturbation, viral replication assays, animal models, and human liver tissue analysis provides a framework for understanding how HBV may sustain immune evasion and persistence.